The major scope of the Proteomics Core Unit is the identification of diagnostic and predictive biomarkers, the discovery of potential drug targets, as well as the elucidation of oncogenic signaling processes. The main activities of the Proteomics Unit relate to translational research topics in the field of acute leukemia, lymphoma, lung cancer, rectal cancer and brain tumors.
- Mass spectrometry: The unit is equipped with three LC/MS systems featuring Q Exactive HF mass spectrometers (Thermo Fisher Scientific), which are used for quantitative protein expression profiling, the analysis of post-translational modifications (e.g. phosphorylation, acetylation and ubiquitination), as well as targeted proteomics and interactome studies. Sample sources range from cell culture models and freshly isolated clinical specimens to fresh-frozen patient-derived material and FFPE-tissues. All required procedures for sample preparation are established at the Proteomics Unit and are available to users.
- Relative quantification of proteins is achieved by stable isotope labeling (e.g. SILAC) and label-free strategies, but also absolute protein quantification.
DKTK Proteomics Unit
University Hospital Frankfurt
Department of Medicine II, Hematology/Oncology
Dr. Thomas Oellerich (Principal investigator)
Tel.: +49 (0)69/6301-84001